Therapeutic Plasma Exchange for Your Practice
Therapeutic plasma exchange has moved steadily out of hospital acute care and into outpatient medicine. It is one of the most substantive procedural expansions available to a longevity, regenerative, or integrative practice, and one of the most operationally demanding. This page is the honest version of what the decision involves.
In short: offering TPE requires an apheresis device, roughly $1,500 per procedure in disposables and albumin, dedicated nursing for the full length of every procedure, apheresis-experienced physician supervision, and written protocols before the first patient. Practices reach that either by building a program independently or by joining an established one. Most underestimate the staffing, not the machine.
Disclosure: I am a Board-Certified Clinical Pathologist and Associate Medical Director at Global Apheresis, which runs an affiliate partnership program for practices adding TPE. I have a commercial interest in that program. I have written this page the way I would want it written if I were the one reading it, which means it includes the reasons not to do this.
The Costs Clinics Plan For, and the Ones They Miss
Most practices price this procedure off the consumables, and the consumables are the easy part. Disposables and albumin come to roughly $1,500 per procedure. That figure is also where a meaningful number of failed programs started, because it excludes the machine, every nursing hour, physician supervision, protocol development, training, and patient acquisition. A clinic that reads $1,500 as its cost per procedure has not costed the procedure. It has costed the supply closet.
The Apheresis Device
Two FDA-cleared machines are available in the United States: the Fresenius Kabi Amicus and the Terumo Spectra Optia. Both are over $100,000 new. This is the line item clinics plan for, and it is rarely the one that sinks a program.
Disposables and Replacement Fluid
Single-use tubing kits, filters, and collection sets run several hundred dollars per patient. Albumin as replacement fluid can approach $1,000 per procedure depending on exchange volume. Together, roughly $1,500 per procedure in direct consumables.
Nursing Hours
Best practice is a nurse with the patient for the entire procedure, monitoring for adverse events and recording vitals every 15 to 20 minutes. Many programs staff two nurses, because some complications are genuinely easier to manage with a second pair of hands. These hours are not optional and they are not in the $1,500.
Physician Supervision
A physician or advanced practice provider supervises the procedure. What separates programs is depth of apheresis experience: whether the person backing up the nurse has managed a citrate reaction or a mid-procedure flow problem before, and is genuinely reachable the moment it happens.
Protocols
Exchange volumes, replacement fluid, session frequency, patient selection, contraindications, and adverse event pathways. Programs that develop these after launch develop them under pressure.
Patient Acquisition
Outpatient TPE is largely cash-pay. A clinic without an existing patient population that both qualifies clinically and can fund the procedure is buying a machine before it has demand.
Does Your Patient Population Actually Support This?
This question comes before equipment, financing, and staffing, and it disqualifies more practices than any other. The American Society for Apheresis describes over 100 indications in its most recent guidelines, and most of them belong in a hospital, either because the presentation is acute or because the payor pathway is already built there. Guillain-Barre syndrome, CIDP, and multiple sclerosis are treated in that setting for good reason.
What Outpatient Programs Actually Treat
In practice, outpatient programs serve patients interested in general health and longevity, post-viral syndromes including Long COVID, mild cognitive decline, and Alzheimer's disease. The evidence base for these indications is growing, and hospital systems routinely turn these patients away even when they offer to pay cash. That gap is the actual opportunity. It is also worth stating plainly that TPE for Alzheimer's is ASFA Category III, and your consent conversations should reflect that.
The Financial Reality
Insurance does not typically cover longevity or wellness indications, so these patients pay out of pocket. Outpatient programs price procedures in a wide range depending on location, overhead, and protocol design, which I have broken down from the patient side in the cost of therapeutic plasma exchange and what insurance does and does not cover. If your patients cannot fund a series of procedures, the rest of this page is academic.
There Is No TPE Certification
This is worth saying clearly, because practices search for it and because the word gets used loosely. There is no accrediting body that certifies a physician or a clinic to perform therapeutic plasma exchange, and no board certification in the procedure itself. Anyone offering you a TPE certification is offering you a training course and a piece of paper. The paper is not a credential.
That does not make training optional. It makes it your responsibility rather than a box to check. Staff need to be genuinely informed about indications, contraindications, timing, parameter selection, and adverse events. The supervising physician should be comfortable with the machine, though in most programs the nurse is the real technical expert. Global Apheresis runs hands-on training for physicians and clinical staff in Dr. Kiprov's protocols. What that covers for a given practice is part of the partnership conversation.
What Actually Substitutes for a Credential
Procedure volume under supervision, and access to someone who has already solved the problem you are about to hit. Dr. Dobri Kiprov is one of the physicians who established therapeutic plasma exchange as a clinical discipline and has overseen more than 15,000 treatments. I have supervised over 500 TPE procedures, and my training pathway ran through clinical pathology and transfusion medicine, which is the discipline the procedure actually belongs to. That is the kind of thing worth asking about, from us or from anyone else.
Build It, or Join One
Building Independently
Source the machine, negotiate the disposables and albumin supply, write your own protocols, arrange your own training, and carry the medical direction yourself. This is entirely doable, and it is the right answer for a practice that already has apheresis or comparable procedural depth in house. You keep the margin and you own every decision. You also own the learning curve, and in a procedure where the patient's blood is outside their body, the learning curve has a cost that is not denominated in dollars.
Joining an Established Program
The alternative is an affiliate partnership, which is what Global Apheresis offers: a turnkey arrangement covering the machine, nursing staff, supplies, and protocols, with medical directorship, hands-on training, and ongoing clinical consultation. Scope and terms depend on the practice and are settled in the contract, so there is no published price, and anyone quoting you one sight unseen is guessing. The affiliate network already spans clinics in several states, so part of that first conversation is whether a given market is open.
How to Choose
The comparison people reach for first is the wrong one. Setting an affiliate fee against $1,500 in consumables compares a program to a supply line. The real comparison is total cost to a safe, staffed, protocolled first procedure, and then to a program with enough volume to stay competent. Run that number honestly for both routes. If you have the procedural infrastructure already, build. If you are starting from a practice that has never run an extracorporeal procedure, the structured route is usually cheaper than it looks and the independent route is usually more expensive than it looks.
When the Answer Is No
I would rather talk a practice out of this than watch it launch badly. A program that starts underprepared does not just fail commercially. It produces a bad outcome, and bad outcomes in outpatient apheresis set back every practice doing this carefully. Reasons to wait:
Your patient population cannot fund a series of procedures, or does not have clear indications. You are counting on insurance. You intend to staff a procedure with a nurse who is also covering other patients. You cannot name who is managing a citrate reaction at 2pm on a Thursday. You are buying the machine first and building demand second. Or the decision is being driven by the fact that a competitor down the road started offering it, which is the worst reason on this list and the most common one.
None of these are permanent disqualifications. They are sequencing problems. The practices that do this well generally fixed them before buying anything. For the full operational detail, including phased implementation timelines, the long version is in the clinical implementation guide.
Physician to Physician
If you are evaluating TPE for your practice, the affiliate program is the right place to start that conversation. The first call is with Dr. Kiprov and me, not a sales team, and it is as useful if you conclude the answer is no.
Or call Global Apheresis directly at (415) 928-1352.